JJP-1008 / JJP Biologics - LARVOL DELTA

JJP-1008: anti-CD270 antibody checkpoint inhibitor for cancer treatment: Swing around patient’s CD270 immunosuppressive disadvantage (FOB-USA 2024) - "High expression of the CD270 on tumors strongly correlates with poor survival and an immunosuppressive TME. Anti-CD270 antibodies were selected that specifically inhibit the interaction with immune suppressive ligands CD160 and BTLA but do not inhibit the immune stimulating CD270-LIGHT interaction"

Checkpoint inhibition • Clinical • Oncology • BTLA • CD70 • TNFRSF14

Anti-HVEM Antibody Checkpoint Inhibitor for Cancer Treatment: Swing around Patient’s HVEM Immunosuppressive Disadvantage (IO-SUMMIT EUROPE 2023) - "Anti-CD270 antibodies were selected that specifically inhibit the interaction with immune suppressive ligands CD160 and BTLA but do not inhibit the immune-stimulating CD270-LIGHT interaction. This turns CD270 expressing tumors from immune suppressive to immune stimulatory."

Checkpoint inhibition • Clinical • Oncology • BTLA • CD70 • TNFRSF14 • TNFRSF18